Company news

Candel Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 10, 2023

Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO

May 1, 2023

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer

April 16, 2023

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

March 29, 2023

Candel Therapeutics to Host Virtual R&D Day on December 6, 2022

November 28, 2022

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

November 17, 2022

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

November 10, 2022

Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

November 9, 2022

Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO

November 6, 2022

Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma

September 14, 2022

Candel Therapeutics Announces Two Executive Leadership Appointments

September 6, 2022

Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

August 4, 2022

Candel Therapeutics Appoints Three New Members to its Board of Directors

July 31, 2022

Candel Therapeutics Announces Release of Initial Data on CAN-2409 in a Phase 2 Clinical Trial Showing Cytotoxic T Cell Response and Disease Control in Patients with Non-Small Cell Lung Cancer

May 25, 2022

Candel Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

May 11, 2022

Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights

March 28, 2022

Candel Therapeutics Appoints Seshu Tyagarajan, Ph.D., RAC, as Chief Technical and Development Officer

March 1, 2022

Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank

February 28, 2022

Candel Therapeutics Appoints Dr. Francesca Barone as Chief Scientific Officer

February 2, 2022

Candel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

November 11, 2021

Candel Therapeutics Presents Novel Biomarker Data Demonstrating Immune Activation After Administration of CAN-3110 in Patients with Recurrent High-Grade Glioma

November 11, 2021

Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies

October 31, 2021

Candel Therapeutics Announces Patient-Reported Tolerability Data of Intraprostatic Injections in Ongoing Phase 3 Clinical Trial of CAN-2409 in Patients with Localized Prostate Cancer

October 27, 2021

Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer

October 18, 2021

Candel Therapeutics Announces Participation in Upcoming Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

October 3, 2021

Candel Therapeutics Announces Participation in Upcoming Scientific Conferences Related to Oncolytic Viral Immunotherapies

September 30, 2021

Candel Therapeutics Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021

September 8, 2021

Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

September 7, 2021

Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer

September 6, 2021

Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters’ Option

August 16, 2021

Candel Therapeutics Announces Pricing of Initial Public Offering

July 25, 2021

← Newer news releases

Decks

The 5 newest of 13 decks. Every deck is listed under its year.